Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas

Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells

Sandra Rotondi, Alessio Modarelli, Maria Antonietta Oliva, Liliya Rostomyan, Patrizia Sanita, Luca Ventura, Adrian F. Daly, Vincenzo Esposito, Adriano Angelucci, Antonietta Arcella, Felice Giangaspero, Albert Beckers, Marie Lise Jaffrain-Rea

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To search for a possible role of Peroxisome Proliferator-Activated Receptor α (PPARα), a molecular partner of the Aryl hydrocarbon receptor Interacting Protein (AIP), in somatotropinomas. Methods: Tumours from 51 acromegalic patients were characterized for PPARα and AIP expression by immunohistochemistry (IHC) and/or Real Time RT-PCR. Data were analysed according to tumour characteristics and pre-operative treatment with somatostatin analogues (SSA). The effects of fenofibrate were studied in GH3 cells in vitro. Results: PPARα was expressed in most somatotropinomas. A modest relationship was found between PPARα and AIP expression, both being significantly higher in the presence of pre-operative SSA. However, only AIP expression was influenced by the response to treatment. Dual effects of fenofibrate were observed in GH3 cells, consisting of cell growth inhibition and an increase in GH secretion inhibited by octreotide. Conclusions: PPARα is a new player in somatotropinomas. Potential interactions between PPARα agonists and SSA may deserve further investigation.

Original languageEnglish
Pages (from-to)61-72
Number of pages12
JournalMolecular and Cellular Endocrinology
Volume426
DOIs
Publication statusPublished - May 5 2016

Fingerprint

Fenofibrate
PPAR alpha
Somatostatin
Tumors
Peroxisome Proliferator-Activated Receptors
Octreotide
Cell growth
Real-Time Polymerase Chain Reaction
Neoplasms
Immunohistochemistry
In Vitro Techniques
aryl hydrocarbon receptor-interacting protein
Therapeutics
Growth

Keywords

  • Acromegaly
  • Aryl hydrocarbon receptor interacting protein (AIP)
  • Fenofibrate
  • GH cells
  • Peroxisome proliferator-activated receptor (PPARα)
  • Somatostatin analogues

ASJC Scopus subject areas

  • Endocrinology
  • Molecular Biology
  • Biochemistry

Cite this

Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas : Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells. / Rotondi, Sandra; Modarelli, Alessio; Oliva, Maria Antonietta; Rostomyan, Liliya; Sanita, Patrizia; Ventura, Luca; Daly, Adrian F.; Esposito, Vincenzo; Angelucci, Adriano; Arcella, Antonietta; Giangaspero, Felice; Beckers, Albert; Jaffrain-Rea, Marie Lise.

In: Molecular and Cellular Endocrinology, Vol. 426, 05.05.2016, p. 61-72.

Research output: Contribution to journalArticle

@article{ee9225ff0230401d9118798be0b40ac5,
title = "Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas: Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells",
abstract = "Purpose: To search for a possible role of Peroxisome Proliferator-Activated Receptor α (PPARα), a molecular partner of the Aryl hydrocarbon receptor Interacting Protein (AIP), in somatotropinomas. Methods: Tumours from 51 acromegalic patients were characterized for PPARα and AIP expression by immunohistochemistry (IHC) and/or Real Time RT-PCR. Data were analysed according to tumour characteristics and pre-operative treatment with somatostatin analogues (SSA). The effects of fenofibrate were studied in GH3 cells in vitro. Results: PPARα was expressed in most somatotropinomas. A modest relationship was found between PPARα and AIP expression, both being significantly higher in the presence of pre-operative SSA. However, only AIP expression was influenced by the response to treatment. Dual effects of fenofibrate were observed in GH3 cells, consisting of cell growth inhibition and an increase in GH secretion inhibited by octreotide. Conclusions: PPARα is a new player in somatotropinomas. Potential interactions between PPARα agonists and SSA may deserve further investigation.",
keywords = "Acromegaly, Aryl hydrocarbon receptor interacting protein (AIP), Fenofibrate, GH cells, Peroxisome proliferator-activated receptor (PPARα), Somatostatin analogues",
author = "Sandra Rotondi and Alessio Modarelli and Oliva, {Maria Antonietta} and Liliya Rostomyan and Patrizia Sanita and Luca Ventura and Daly, {Adrian F.} and Vincenzo Esposito and Adriano Angelucci and Antonietta Arcella and Felice Giangaspero and Albert Beckers and Jaffrain-Rea, {Marie Lise}",
year = "2016",
month = "5",
day = "5",
doi = "10.1016/j.mce.2016.02.005",
language = "English",
volume = "426",
pages = "61--72",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Expression of Peroxisome Proliferator-Activated Receptor alpha (PPARα) in somatotropinomas

T2 - Relationship with Aryl hydrocarbon receptor Interacting Protein (AIP) and in vitro effects of fenofibrate in GH3 cells

AU - Rotondi, Sandra

AU - Modarelli, Alessio

AU - Oliva, Maria Antonietta

AU - Rostomyan, Liliya

AU - Sanita, Patrizia

AU - Ventura, Luca

AU - Daly, Adrian F.

AU - Esposito, Vincenzo

AU - Angelucci, Adriano

AU - Arcella, Antonietta

AU - Giangaspero, Felice

AU - Beckers, Albert

AU - Jaffrain-Rea, Marie Lise

PY - 2016/5/5

Y1 - 2016/5/5

N2 - Purpose: To search for a possible role of Peroxisome Proliferator-Activated Receptor α (PPARα), a molecular partner of the Aryl hydrocarbon receptor Interacting Protein (AIP), in somatotropinomas. Methods: Tumours from 51 acromegalic patients were characterized for PPARα and AIP expression by immunohistochemistry (IHC) and/or Real Time RT-PCR. Data were analysed according to tumour characteristics and pre-operative treatment with somatostatin analogues (SSA). The effects of fenofibrate were studied in GH3 cells in vitro. Results: PPARα was expressed in most somatotropinomas. A modest relationship was found between PPARα and AIP expression, both being significantly higher in the presence of pre-operative SSA. However, only AIP expression was influenced by the response to treatment. Dual effects of fenofibrate were observed in GH3 cells, consisting of cell growth inhibition and an increase in GH secretion inhibited by octreotide. Conclusions: PPARα is a new player in somatotropinomas. Potential interactions between PPARα agonists and SSA may deserve further investigation.

AB - Purpose: To search for a possible role of Peroxisome Proliferator-Activated Receptor α (PPARα), a molecular partner of the Aryl hydrocarbon receptor Interacting Protein (AIP), in somatotropinomas. Methods: Tumours from 51 acromegalic patients were characterized for PPARα and AIP expression by immunohistochemistry (IHC) and/or Real Time RT-PCR. Data were analysed according to tumour characteristics and pre-operative treatment with somatostatin analogues (SSA). The effects of fenofibrate were studied in GH3 cells in vitro. Results: PPARα was expressed in most somatotropinomas. A modest relationship was found between PPARα and AIP expression, both being significantly higher in the presence of pre-operative SSA. However, only AIP expression was influenced by the response to treatment. Dual effects of fenofibrate were observed in GH3 cells, consisting of cell growth inhibition and an increase in GH secretion inhibited by octreotide. Conclusions: PPARα is a new player in somatotropinomas. Potential interactions between PPARα agonists and SSA may deserve further investigation.

KW - Acromegaly

KW - Aryl hydrocarbon receptor interacting protein (AIP)

KW - Fenofibrate

KW - GH cells

KW - Peroxisome proliferator-activated receptor (PPARα)

KW - Somatostatin analogues

UR - http://www.scopus.com/inward/record.url?scp=84961990987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961990987&partnerID=8YFLogxK

U2 - 10.1016/j.mce.2016.02.005

DO - 10.1016/j.mce.2016.02.005

M3 - Article

VL - 426

SP - 61

EP - 72

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

ER -